Male Hypogonadism Guidelines Compared: ADA, AACE, Endocrine Society, AUA, and EAU

The Shared Starting Point

Low testosterone on a single laboratory report is not, by itself, a diagnosis. The Endocrine Society recommends making the diagnosis only in men with symptoms and signs consistent with testosterone deficiency and consistently, unequivocally low serum testosterone. It also recommends repeating a morning fasting total testosterone measurement to confirm the result. The guideline emphasizes use of an accurate assay and reference ranges appropriate to that assay rather than treating one internet cutoff as universally diagnostic [1].

The AUA similarly requires both symptoms or signs and biochemical evidence. Its guideline uses total testosterone below 300 ng/dL as a reasonable cutoff and recommends two separate early-morning total-testosterone measurements [2]. The AUA cutoff is a clinical decision threshold, not a substitute for considering assay quality, acute illness, medications, sleep, and the patient’s symptoms.

The EAU diagnostic pathway also starts with symptoms and repeat morning, fasting total testosterone measurements. Its current male-hypogonadism chapter uses 12 nmol/L as a practical total-testosterone threshold and discusses additional assessment when the total result is borderline or sex hormone-binding globulin, or SHBG, could make total testosterone misleading [3]. Twelve nmol/L is about 346 ng/dL. It is therefore inaccurate to describe the EAU as using a universal cutoff of 264 ng/dL.

Where the Guidance Actually Differs

The Endocrine Society gives the most detailed framework for confirming a biochemical diagnosis. It advises free testosterone measurement when the total value is near the lower limit of normal or when an altered SHBG concentration is suspected. Obesity, aging, thyroid disease, liver disease, and some medicines can affect SHBG and complicate interpretation. A calculated or equilibrium-dialysis free testosterone result is useful only when the laboratory method and clinical question are appropriate [1].

The AUA provides a more operational diagnostic cutoff and a broad urology-focused evaluation pathway. It does not make free testosterone a required first test for every patient. Instead, free testosterone can be helpful when total testosterone is equivocal or symptoms and total testosterone do not fit together [2].

The EAU presents testosterone deficiency in the context of sexual and reproductive health. Its pathway is especially useful for distinguishing organic hypogonadism from potentially reversible functional suppression related to obesity, systemic illness, or medicines. That distinction matters because treating the contributing condition can be an important part of care, whether or not testosterone therapy is eventually used [3].

ADA and AACE publications are important for diabetes, obesity, cardiovascular risk, and medication management. They do not create a second, competing universal diagnosis of male hypogonadism for a patient who does not have those conditions. In a patient with type 2 diabetes or obesity, clinicians should evaluate symptoms, repeat testosterone testing when indicated, and address the metabolic disease alongside the testosterone question.

Starting Treatment

All three primary guideline sources support treatment only after a confirmed diagnosis and a discussion of expected benefits, limits, burdens, and risks. Testosterone therapy is not a treatment for nonspecific fatigue alone and is not a fertility treatment. Exogenous testosterone suppresses gonadotropin signaling and can reduce sperm production. The Endocrine Society recommends against starting therapy in men planning fertility in the near term [1]. Patients seeking fertility need an individualized reproductive-urology or endocrinology plan rather than routine testosterone replacement.

Contraindications and cautions are product- and patient-specific. The Endocrine Society lists conditions in which therapy should not be started, including prostate or breast cancer, markedly elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, thrombophilia, and near-term fertility plans [1]. The exact evaluation before treatment should be chosen with the prescriber and should not be reduced to a checklist copied from a different guideline.

The 2023 TRAVERSE trial found that testosterone replacement was noninferior to placebo for major adverse cardiovascular events in the studied population of men with hypogonadism and preexisting or high cardiovascular risk. That result does not make testosterone appropriate for every older man, and it should not be used to override labeled contraindications or an individual cardiovascular assessment [4].

Monitoring and a Practical Comparison

Monitoring is not identical for every formulation. The Endocrine Society recommends evaluating response, adverse effects, testosterone concentration, and hematocrit after treatment starts; prostate monitoring is individualized through shared decision-making [1]. The AUA also calls for baseline hemoglobin or hematocrit and continued follow-up for treatment response and safety [2]. Use the prescribing information for the selected injection, gel, patch, pellet, nasal product, or oral product when choosing the timing of a testosterone level, because timing can differ substantially by formulation.

The useful comparison is therefore not which guideline is "most permissive." It is which source answers the clinical question at hand. Use the Endocrine Society guidance for diagnosis and endocrine contraindications, the AUA guidance for a urology-oriented diagnostic and follow-up framework, and the EAU pathway for its current sexual-and-reproductive-health context. When diabetes, obesity, infertility, cancer history, sleep apnea, erythrocytosis, or major cardiovascular disease is present, the decision often needs input beyond a single testosterone guideline.

Getting the Blood Tests Right

Morning testing is not a bureaucratic hurdle. Testosterone has biologic variation, and total testosterone can be temporarily lower with acute illness, inadequate sleep, substantial caloric restriction, or some medicines. The Endocrine Society therefore calls for repeat morning fasting total-testosterone testing before diagnosis [1]. A result obtained while a patient is acutely unwell may need to be repeated after recovery rather than used to start lifelong treatment.

Laboratories use different methods and reference intervals. The Endocrine Society advises use of accurate assays and rigorously derived reference ranges [1]. A pooled analysis of four cohorts that used standardized measurements estimated a harmonized reference range of 264 to 916 ng/dL for healthy, nonobese men aged 19 to 39 years [5]. That research is helpful for interpreting an assay, but it does not turn 264 ng/dL into a universal treatment threshold for every age, laboratory, or clinical setting.

If repeat total testosterone is low, guidelines move on to cause and context. The Endocrine Society recommends measuring luteinizing hormone and follicle-stimulating hormone to distinguish primary from secondary hypogonadism and pursuing further evaluation when indicated [1]. That workup can identify a pituitary, testicular, medication-related, systemic-illness, or functional contributor. A guideline comparison should not imply that testosterone replacement is the automatic next step after a low result.

Older Men and Age-Related Symptoms

Older men often have symptoms with multiple possible causes, including sleep disorders, depression, medication effects, anemia, thyroid disease, chronic pain, and vascular disease. The Testosterone Trials studied 790 men aged 65 years or older with low testosterone and found some benefits in sexual function, but effects varied by outcome [6]. The trial does not establish that testosterone treats nonspecific symptoms in every older patient.

The American College of Physicians recommends discussing testosterone treatment with men who have age-related low testosterone and want to improve sexual function, while advising that treatment not be initiated to improve energy, vitality, physical function, or cognition because evidence does not support those uses [7]. It recommends reevaluating symptoms within 12 months and stopping therapy if sexual function does not improve [7]. This is a treatment-purpose recommendation, not a diagnostic definition that replaces the Endocrine Society, AUA, or EAU framework.

The individual Testosterone Trials show why the outcome must be named. One year of testosterone increased volumetric bone density and estimated bone strength in the bone substudy [14], and it increased hemoglobin in many participants with anemia [15]. The cognitive substudy found no improvement in memory or other measured cognitive functions [16]. A coronary-computed-tomography substudy found a greater increase in noncalcified coronary plaque volume with testosterone than placebo, although it was not designed to determine clinical cardiovascular events [17]. In the larger TRAVERSE fracture substudy, clinical fractures were more frequent in the testosterone group, so an increase in bone density should not be presented as proven fracture prevention [18]. These results cannot be collapsed into a claim that testosterone either helps or harms every older man.

The AUA statement that age alone should not exclude treatment should likewise be read with its requirement for symptoms, confirmed low testosterone, counseling, and follow-up [2]. A patient and clinician can reasonably decide against treatment even if the laboratory criterion is met, especially when a reversible driver has not yet been addressed.

Fertility, Formulation, and Product-Specific Safety

Testosterone products are not fertility medicines. The Endocrine Society recommends against testosterone therapy in men planning fertility in the near term [1]. The AUA/ASRM male-infertility guideline similarly addresses evaluation and treatment of infertility separately from routine testosterone replacement [9]. A person concerned about present or future fertility should say so before treatment, because the evaluation and possible alternatives are different.

Once treatment is selected, the formulation should be chosen with the label in hand. Injection, gel, solution, nasal, oral, and implantable products have different administration techniques, timing of serum testing, transfer precautions, and adverse-effect warnings. The DailyMed label for testosterone cypionate, for example, is not interchangeable with the label for a gel or oral testosterone product [10]. A generic target range copied from another formulation can lead to a poorly timed blood draw or an inappropriate adjustment.

Topical gels create a separate household-exposure question. The current AndroGel label includes measures intended to reduce secondary exposure to women and children, such as washing hands after application and covering the application site when contact is expected [12]. This is one reason a formulation decision should consider daily routine and household contacts as well as cost and convenience.

Oral testosterone undecanoate has a different label, administration regimen, and monitoring considerations from injectable testosterone and gels [13]. A clinician should therefore prescribe and monitor the named product, rather than treating the word "testosterone" as one interchangeable dose form.

The Food and Drug Administration requires labeling that limits prescription testosterone to men with low testosterone associated with certain medical conditions and advises clinicians to discuss potential cardiovascular risk before treatment [8]. FDA communications and labels evolve, so a current product label and the prescriber’s assessment should control rather than a dated online summary. The CDC Hormone Standardization program is also relevant to testing quality, because standardization aims to improve comparability of testosterone and estradiol measurements across laboratories [11].

A Practical Visit Framework

An efficient assessment usually answers five questions: are there compatible symptoms or signs; were two properly timed tests low on an appropriate assay; is free testosterone needed because the total result or SHBG is difficult to interpret; is there a reversible or serious cause to evaluate; and what treatment goal matters to the patient? A sixth question, fertility plans, should be answered before any prescription is written.

For follow-up, document the formulation, timing of the dose relative to the blood draw, symptoms that are expected to change, hematocrit, and the relevant prostate and cardiovascular discussion. This approach preserves the common ground across the guidelines without pretending that each society recommends the same cutoff, testing sequence, or treatment goal.